anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intrinsically disordered protein α-Synuclein is identified as a major toxic aggregate in Parkinson's as well as several other neurodegenerative diseases. Recent work on this protein has focused on the effects of posttranslational modifications on aggregation kinetics. Among them, O-GlcNAcylation of α-Synuclein has been observed to inhibit the aggregation propensity of the protein. Here, we investigate the monomer dynamics of two O-GlcNAcylated α-Synucleins, α-Syn(gT72), and α-Syn(gS87) and correlate them with the aggregation kinetics. We find that, compared to the unmodified protein, glycosylation at T72 makes the protein less compact and more diffusive, while glycosylation at S87 makes the protein more compact and less diffusive. Based on a model of the earliest steps in aggregation, we predict that T72 should aggregate slower than unmodified protein, which is confirmed by ThT fluorescence measurements. In contrast, S87 should aggregate faster, which is not mirrored in ThT kinetics of later fibril formation but does not rule out a higher rate of formation of small oligomers. Together, these results show that posttranslational modifications do not uniformly affect aggregation propensity.
OBJECTIVES: To explore whether the gap junction (GJ) composed by connexin32(Cx32) mediated pyroptosis in renal ischemia-reperfusion(I/R) injury via transmitting miR155-3p, with aim to provide new strategies for the prevention and treatment of acute kidney injury (AKI) after renal I/R.
METHODS: 8-10 weeks of male C57BL/ 6 wild-type mice and Cx32 knockdown mice were divided into two groups respectively: control group and renal I/R group. MCC950 (50 mg/kg. ip.) was used to inhibit NLRP3 in vivo. Human kidney tubular epithelial cells (HK - 2) and rat kidney tubular epithelial cells (NRK-52E) were divided into high-density group and low-density group, and treated with hypoxia reoxygenation (H/R) to mimic I/R. The siRNA and plasmid of Cx32, mimic and inhibitor of miR155-3p were transfected into HK - 2 cells respectively. Kidney pathological and functional injuries were measured. Western Blot and immunofluorescent staining were used to observe the expression of NLRP3, GSDMD, GSDMD-N, IL - 18, and mature IL-18. The secretion of IL-18 and IL-1β in serum, kidney tissue and cells supernatant were detected by enzyme-linked immuno sorbent assay (ELISA) kit, and the expression of NLPR3 and miR155-3p were detected by RT-qPCR and fluorescence in situ hybridization (FISH).
RESULTS: Tubular pyroptosis were found to promote AKI after I/R in vivo and Cx32-GJ regulated pyroptosis by affecting the expression of miR155-3p after renal I/R injury. In vitro, H/R could lead to pyroptosis in HK-2 and NRK-52E cells. When the GJ channels were not formed, and Cx32 was inhibited or knockdown, the expression of miR155-3p was significantly reduced and the pyroptosis was obviously inhibited, leading to the reduction of injury and the increase of survival rate. Moreover, regulating the level of miR155-3p could affect survival rate and pyroptosis in vitro after H/R.
CONCLUSIONS: The GJ channels composed of Cx32 regulated tubular pyroptosis in renal I/R injury by transmitting miR155-3p. Inhibition of Cx32 could reduce the level of miR155-3p further to inhibit pyroptosis, leading to alleviation of renal I/R injury which provided a new strategy for preventing the occurrence of AKI. Video Abstract.
A patient anonymizing system includes a plurality of hashing appliances and data sources. Each appliance receives medical records containing at least confidential protected health information (PHI). A salt value is appended to each confidential PHI, and a hash is generated, which replaces the confidential PHI to generate an anonymized record. A master patient index server aggregates the anonymized records. A vector and cluster matching engine determines if the anonymized record matches a unique patient identifier corresponding to a second anonymized record. A comparison vector is generated by comparing hash values of the confidential PHI with hash values in the second anonymized record, and is crossed with a confidence vector having weights based on match conditions. This produces a match confidence level, which is compared to a threshold. If the threshold is met, the anonymized record is mapped to the unique patient identifier associated with the second record.
The invention belongs to the technical field of traditional Chinese pharmacology, and particularly relates to a thrombolytic pure Chinese drug preparation. The thrombolytic pure Chinese drug preparation comprises astragalus, ground beetle, safflower, cowherb seed, earthworm, honeysuckle flower, leech, uncaria, arisaema cum bile, peach kernel, Chinese taxillus twig, szechuan lovage rhizome, medicinal cyathula root, clematis root, indian buead, beautiful sweetgum fruit, ginseng, chrysanthemum, centipede, suberect spatholobus stem, scorpio, liquoric root, dragon's blood, Chinese angelica, pseudo-ginseng root, dwarf lilyturf root, large-head atractylodes rhizome, longan pulp, tuber fleeceflower root, bauhinia root and the like. The thrombolytic pure Chinese drug preparation is used for promoting blood circulation to remove blood stasis, removing heat to cool blood, ventilating to restore consciousness, expelling wind to dredge collateral and promoting blood flow. All the components cooperate to achieve the effects of tonifying qi, activating the blood, dispersing the blood stasis and dredging the collateral, thrombosis symptoms are quickly and effectively relieved, and the thrombolytic aim is achieved fundamentally. The treatment effect is remarkable, side effects are little, and the cost is low. The compatibility of selected medicines is suitable, the traditional Chinese medicine and modern pharmacology research theory is met, the thrombolytic pure Chinese drug preparation is low in cost and worthy of being widely popularized and applied, and the toxic and side effects are completely avoided.
The effects of custirsen will be evaluated following administration of a single dose following dose-titration period combined with dexamethasone pretreatment. On days -1 and 7, subjects will undergo a full ECG assessment for 24 hours. On day 1, randomization and assignment to the treatment groups will be performed prior to drug administration. Subjects will remain in the study center throughout the treatment period. All subjects will be discharged at the end of day 8 procedures, 24 hours after the last dose of custirsen has been administered. Subjects in groups 1 and 2 will return for an additional visit on day 9, 10 and 14 (±2 days) (approximately 7 days after the last study drug administration). Subjects in group 3 will not return for a follow-up visits.
Despite obesity is a cardiovascular risk factor, numerous studies have identified a better prognosis in overweight and obese heart failure (HF) patients. This paradox has been named "the obesity paradox". However, this paradox has been criticized because the parameter used to classify obesity, the body mass index (BMI), has several limitations. Obesity is defined as an abnormal or excessive fat accumulation, and BMI does not always reflect real body fat.

What is more, patients with HF can have their body composition altered with hyperhydration or undernourishment. A pilot study proved that BMI does not indicate true nutritional status in HF. Thus, a further assessment of body composition of HF patients, analyzing the nutritional status rather BMI, could shed light on the obesity paradox. The aim of this study was to assess the nutritional status of a cohort of HF patients, its correspondence with BMI, and its significance in terms of survival.
All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
Patients receive SARS-COV-2 specific cytotoxic T lymphocytes IV over 30 minutes on day 1. Treatment may repeat every 14 days at investigators' discretion if patient fails to respond, the infection reoccurs, until the viral load becomes negative or until complete resolution of clinical and radiological signs.
Frequent discussions in the tumour board about the Residual tumour (R) Classification of the UICC's "TNM Classification of Malignant Tumours", especially in the case of breast surgery specimens, raised the question about differing interpretations amongst different medical specialties. Thus, we designed a survey about the R Classification with a special focus on breast cancer specimens. An online survey was conducted, where a web link to the survey was distributed via email to various medical professional societies dealing with breast cancer in Austria and Germany with the request to distribute the link to their members. The study population consisted of physicians of all educational levels of different medical professions, who deal with breast carcinomas in their daily routine. Two hundred two participants, of which 160 (79.2%) have more than 10 years' professional experience, took part in the survey; 88 (43.6%) were surgeons/gynaecologists, 80 (39.6%) pathologists, 19 (9.4%) radiation oncologists/ therapists, 8 (4.0%) radiologists, and 7 (3.5%) oncologists. We show that the R Classification is not completely mastered by anyone and that there are significant differences in the interpretation of the R Classification between different medical specialties. For better differentiation between the residual tumour (R Classification) of the TNM and a pure resection margin assessment, we suggest the use of a Resection margin (Rm) Classification to avoid further misunderstandings. To assist better multidisciplinary cooperation and to ensure better patient care all medical disciplines should be educated about the actual meaning and correct application of the R Classification.
Patients receive online adaptive radiotherapy with 5-10mm PTV margin. The CTV contours of the following areas: gross tumor volume (GTV), cervix (if not already encompassed by the GTV), uterus, parametria, ovaries, vaginal tissue, obturator nodal chain, internal iliac nodal chain, external iliac nodal chain, presacral nodal chain and common iliac nodal chain. The upper border of CTV is at the level of aortic bifurcation. A dose of 50.4Gy is delivered to CTV with online adaptive radiotherapy.
The planned clinical study 986 (TREAT 2b) is a 24-week study in patients with Active rheumatoid arthritis (RA) who have had an inadequate response to Methotrexate (MTX) alone. The main phase of this study is followed by a 24-week extension phase for subjects meeting the respective entry criteria. Patients will be randomized to one of three different Active treatment groups or Placebo. The primary efficacy variable is the proportion of subjects with an ACR20 response after 12 weeks of double blinded treatment with the study medication based on observed cases in the FAS.

At Week 12, all subjects who had a minimum improvement of at least 20% (from baseline) in their tender joint count (TJC) and swollen joint count (SJC) continued on the same treatment. Subjects who had not demonstrated an improvement of at least 20% of TJC and SJC were assessed as non-responders. Non-responders who received placebo were randomized to an active treatment dose in a blinded manner. Non-responders who received active treatment were rolled up to the next highest dose in a blinded manner, apart from those already on the highest dose. These subjects remained on the highest dose.
Participants will attend 8 weekly chiropractic visits (40-minutes for initial visit, 20-minutes for remaining 7). Participants will simultaneously enroll in 8 weekly 90-minute virtual group medical visits.
One 45 minutes session of stimulation. The stimulation coil will be located in the precuneus, located in the Pz area of the 10-20. The coil will not emit any magnetic field.
A method for assaying hu-Asp1   a  -secretase activity is claimed, comprising contacting hu-Asp1 protein with an amyloid precursor protein (APP) substrate containing an   a  -secretase cleavage site and measuring the cleavage of said substrate at said site. The hu-Asp1 amino acid sequence may comprise the sequence of SEQ ID NO:2 or preferably modified sequences are claimed lacking the amino terminal domain, transmembrane domain or cytoplasmic domain. Methods of identifying modulators of hu-Asp1   a  -secretase activity as candidate Alzheimer's disease modulators and their use in therapeutic compositions are also claimed. Preferably the APP substrate contains the   a  -secretase cleavage site LVFFAEDF or KLVFFAED. Alternatively claimed is a hu-Asp1 substrate peptide comprising 50 or fewer amino acids including the cleavage site GLALALEP and methods of assaying hu-Asp1 proteolytic cleavage. The Hu-Asp2   b  -secretase gene, polypeptide and assay for   b  -secretase activity is also described.
The proposed study aims to describe presymptomatic and at-risk individuals' patterns of disclosure about Huntington's disease (HD) and HD risk to family and friends, and to investigate whether an association exists between disclosure about HD and psychological adaptation to HD. HD is reported to be one of the conditions most frequently involved in cases of nondisclosure about genetic risk. Little is known about the extent of disclosure and the process of disclosure within the HD population. Evidence suggests that a relationship may exist between disclosure of one's condition to others and psychological adaptation to the condition; however, this theory has never been tested. The conceptual framework of the study is informed by Shelly Taylor's Theory of Cognitive Adaptation. We will use a cross-sectional survey to 1) investigate individuals' patterns of disclosure about HD and 2) assess psychological adaptation to HD. Participants will be recruited from HD clinics, HD support groups, HD websites, and HD online mailing listservs. Eligible participants will be asked to complete either a web-based or a paper survey. The main outcome measure is psychological adaptation to HD.
A server according to an embodiment may receive information of hospital or clinic from a user′s terminal. The server may receive the user′s medical record from the terminal of a hospital or a clinic. The server may generate a second medical record by processing the received medical record. The server may provide the second medical record to the user′s terminal. The server may receive information of a second hospital and clinic from the user′s terminal. The server may receive a request for transmission of a previously generated medical record from the user′s terminal. The server may provide a previously generated medical record to the user′s terminal and the second terminal of the second hospital in response to the transmission request. The server may receive a newly created medical record from the second terminal and process the received medical record, and provide the processed medical record to the user′s terminal.
A convenience sample will be drawn from 6 Congregate Dining (CD) groups in the Chinese community. There are six groups of CD programs run by Yee Hong Centre for Geriatric Care run at different locations in the Greater Toronto Area. The screening will be offered on site at regular CD meetings to participants who have given informed, written consent. All participants will attend a private post-screening interview. Those who score above the threshold for depression and/or cognitive impairment, and who have not previously been diagnosed or treated for these conditions, will be randomly assigned to one of two groups: an intervention group and a usual care group. Participants in the intervention group will receive their screening results at the post-screening interviews and will also be provided with suggestions for possible follow-up. They will be given the option of receiving further psychiatric assessment at the Wellness Centre, or seeking care with their family physician and assisted to obtain further care, if desired. Participants in the intervention group will attend an appointment 3 months after receiving screening results and follow-up options during which the rate of help seeking, rate of confirmed psychiatric diagnoses and types of intervention received will be determined. Participants in the usual care group will not be given screening results at the post-screening interview but will instead attend an appointment 3 months post screening to receive their results and information about follow-up options.

The results of this research will: demonstrate whether community living Chinese elders are at greater risk of psychiatric disorders and demonstrate the need for screening in older Chinese adults living in the community; aid in the development of systematic and targeted community-based screening and outreach to at-risk members of the target population; and help determine if identification of mental health issues and education about treatment resources has any effect on help-seeking for those conditions.
PURPOSE: A composition including extract of ground part in curcumae longae rhizoma or the non-polar organic solvent fractions thereof are provided to be useful for preventing and treating IL-6 induced STAT3 mediated diseases, cancer or inflammatory diseases. CONSTITUTION: A composition for preventing and treating IL-6 induced STAT3 mediated diseases includes extract of ground part in curcuma longa L or curcuma aromatica L as active ingredient. The extract is obtained by extracting the ground part of curcuma longa L or curcuma aromatica L by using water, organic solvent or a mixed solvent thereof. The organic solvent is methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butylacetate, dichloromethane, N,N- dimethylformamid (DMF), dimethyl sulfoxide (DMSO), 1,3- butylene glycol, propylene glycol or a mixed solvent thereof. A non-polar organic solvent fraction is obtained by disjunct-extracting the extract with hexane, ether, dichloromethane, chloroform, ethyl acetate or a mixed solvent thereof. The IL-6 induced STAT3 mediated disease is cancer or inflammation disease.
For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. 

Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
251,373. Burlin, A. L., Leicester, S., and Holman, L. B. Feb. 11, 1925. Teeth, artificial; palates, artificial.-Dentures, artificial palates and the like are moulded from water-insoluble organic esters or ethers of cellulose such as the acetate. The compositions employed contain also colloiding agents or plasticisers such as benzyl alcohol, benzoin, benzil, or triacetin, and pigments such as white titanium pigments and vermilion. Solvents to be volatilized from the mass may also be employed. The material may be prepared in plate or sheet form, or as pre-formed blanks, or in pulverulent form. In forming a denture the teeth embedded in wax are inserted with the base upward in plaster in one half of a flask, the wax removed as usual, the two halves of the flask heated, and the cellulose composition inserted. The two halves of the flask are then brought together, heated to 160‹ C. in a press under direct dry heat, and pressure gradually applied until the flask is completely closed. The flask is then removed with the press from the heater, placed in cold water and the denture removed and finished in the usual manner. For repair work part of the denture is cut away and a new tooth inserted in place on modelling wax, and the plate so prepared is invested in plaster, the wax removed and replaced by the cellulose composition, and the whole treated in a press as above described. Alternatively a new portion may be secured by the employment of volatile solvents.
The overall survival of patients with pancreatic cancer (PC) is dismal and has only improved slightly during the last decades primarily due to combination chemotherapy. Early detection of PC is difficult and less than 25% of all PC patients are operated. No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers, which can be used to 1) diagnose PC early in the disease course with high specificity and sensitivity, 2) improve prognostication, or 3) predict and monitor treatment effectiveness and tolerability for the individual patient.

BIOPAC is an observational and translational open cohort study with prospective collection of biological materials and clinical data in patients with PC treated in routine care and also patients who were suspicious for malignancy in the pancreas but then operated without evidence of malignancy. Patients contribute with blood samples (i.e. serum, EDTA plasma and buffy coat, and blood in PAXgeneRNA tubes) before operation or start of adjuvant or palliative chemotherapy and during treatment with blood sampling before 2. cycle of chemotherapy and longitudinally every time of CT scan until disease progression. This schedule is repeated if patients are treated with subsequent lines of chemotherapy. The patients are followed until death. Demographics, disease characteristics, comorbidities and lifestyle factors are registered at inclusion; weight and performance status at each treatment cycle; routine blood tests (i.e. haematology, creatinine, liver enzymes, bilirubin, carbohydrate antigen 19-9, C-reactive protein); type of operation; types of chemotherapy and number of cycles given; date of disease recurrence in operated patients; date of disease progression for each line of chemotherapy; and date of death. Biomarker analyses will include a range of molecules with different characteristics such as DNA, Single Nucleotide Polymorphism (SNPs), RNA, microRNA, proteins and metabolites. Data will be analysed using appropriate methods and statistical analyses.
In inflamed tissues, monocytes differentiate into macrophages (mo-Mac) or dendritic cells (mo-DC). In chronic non-resolving inflammation, mo-DC are major drivers of pathogenic events. Manipulating monocyte differentiation would therefore represent an attractive therapeutic strategy. Here the inventors show that the transcriptional repressors ETV3 and ETV6 control monocyte differentiation into mo-DC. To validate the physiological relevance of these findings, the inventors generated mice deficient for ETV6 in monocytes. Deficient mice show spontaneous expression of interferon-stimulated genes, confirming that ETV6 regulates interferon responses in vivo. Furthermore, deficient mice display impaired mo-DC differentiation during peritonitis and less severe symptoms in experimental autoimmune encephalomyelitis. The findings identify ETV3 and ETV6 as a therapeutic target to redirect monocyte differentiation in inflammatory disorders.